Pereira Juliano Lacava, Volcão Lisiane Martins, Klafke Gabriel Baracy, Vieira Roseli Stone, Gonçalves Carla Vitola, Ramis Ivy Bastos, da Silva Pedro Eduardo Almeida, von Groll Andrea
1 Faculdade de Medicina, Medical Microbiology Research Center (NUPEMM), Universidade Federal do Rio Grande-FURG , Rio Grande, Brazil .
2 Faculdade de Medicina, Universidade Federal do Rio Grande-FURG , Rio Grande, Brazil .
Microb Drug Resist. 2019 Mar;25(2):173-181. doi: 10.1089/mdr.2018.0046. Epub 2018 Aug 22.
The objective of this study was to evaluate the frequency of different extended-spectrum β-lactamases (ESBL) as well as to associate these ESBL with antimicrobial (ATM) resistance in Escherichia coli and Klebsiella spp. isolates from outpatients and inpatients with urinary tract infections. The study included 435 consecutive nonduplicate clinical isolates, including 362 E. coli isolates, 62 Klebsiella pneumoniae isolates, and 11 K. oxytoca isolates. Isolates were obtained from patients who were treated in a University Hospital between August 2012 and July 2013. Three multiplex PCR were performed to identify the ESBL groups. A total of 48 (11%) ESBL-producing isolates were found. The risk for the ESBL presence was significantly higher in males (26.4%) than females (8%), from hospital-acquired infections (29.1%) than community-acquired infections (7.0%) and in Klebsiella spp. (27.4%) than in E. coli (7.7%). ESBL-producing isolates presented a significantly higher percentage of resistance in 21 of the 23 ATMs analyzed. The CTX-M-1 group was the most predominant ESBL identified. The bla gene was found in 56% of the total ESBL producers from community and in 42.4% from hospital origins; it was followed in frequency by the bla, also found in both environments. Klebsiella spp. presented the largest variety of β-lactamase enzyme combinations and a higher level of resistance to cefotaxime. These findings contribute to better knowledge of the epidemiology of ESBL enzymes and are alarming for the reduced therapeutic options available for the risk groups identified in the studied populations.
本研究的目的是评估不同超广谱β-内酰胺酶(ESBL)的频率,并将这些ESBL与尿路感染门诊和住院患者的大肠杆菌及克雷伯菌属分离株中的抗菌药物(ATM)耐药性相关联。该研究纳入了435株连续的非重复临床分离株,包括362株大肠杆菌分离株、62株肺炎克雷伯菌分离株和11株产酸克雷伯菌分离株。分离株取自2012年8月至2013年7月在一家大学医院接受治疗的患者。进行了三次多重PCR以鉴定ESBL组。共发现48株(11%)产ESBL分离株。男性(26.4%)产ESBL的风险显著高于女性(8%),医院获得性感染(29.1%)高于社区获得性感染(7.0%),克雷伯菌属(27.4%)高于大肠杆菌(7.7%)。在分析的23种ATM中,产ESBL分离株对其中21种的耐药百分比显著更高。CTX-M-1组是鉴定出的最主要的ESBL。bla基因在社区来源的ESBL生产者中占56%,在医院来源的中占42.4%;其次是bla,在两种环境中均有发现。克雷伯菌属呈现出最多样化的β-内酰胺酶组合,对头孢噻肟的耐药水平更高。这些发现有助于更好地了解ESBL酶的流行病学情况,且对于所研究人群中确定的风险组可用治疗选择的减少令人担忧。